Clinical Trial Update: Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil to prevent graft-versus-host disease after donor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Graft-versus-host Disease
• Myelodysplastic Syndrome

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Emapalumab (emapalumab)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Status: NOT_YET_RECRUITING